Kudos to client and women’s contraceptive health innovator Evofem Biosciences (OTCQB: EVFM) on acquiring the women’s health specialty business of global pharma Lupin Limited. This secures Evofem the FDA-approved single-dose antimicrobial agent Solosec®, which provides a complete course of therapy for two common sexual health infections.

Evofem already markets Phexxi®, an FDA-approved hormone-free, on-demand prescription contraceptive vaginal gel. The company has just secured a License and Supply Agreement for the Middle East rights to Phexxi® with private Emirati health care company Pharma 1 Drug Store LLC.

Procopio Senior Counsel Jennifer Trowbridge led the Solosec® deal for Evofem with the assistance of Mergers & Acquisitions practice co-leader Paul Johnson. Handling complex IP due diligence in the deal was Life Sciences practice co-leader Frank Yang with assistance by Raph Kim.

“The acquisition of this commercial business aligns with and advances our mission to improve access to innovative and differentiated options that impact women’s daily lives,” said Evofem CEO Saundra Pelletier. “We can now fully leverage our commercial infrastructure, maximize our strong physician relationships, and re-launch an asset with tremendous growth potential.”

In 2023, Procopio IP Litigation attorneys successfully fended off a generic company’s challenge to key Evofem patents in an Abbreviated New Drug Application (ANDA) dispute, with Partners Jeremy Edwards and Steve Maddox serving as Evofem litigation counsel.

Learn more about the Solosec® transaction in their July 15, 2024, press release.